Stock listing

NASDAQ:KPTI Karyopharm Therapeutics Inc. Stock

Home listing (NASDAQ) of Karyopharm Therapeutics Inc.

Follow Karyopharm Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:KPTI

$0.39 USD +0.04 (+11.2%)

Close on Oct 16, 2026

Since Jul 6, 2026 -95.9% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$0.33 – $0.40 USDOct 16, 2026
Volume
2.69M sharesOct 16, 2026
Market value
$8.85M USDAt the close on Oct 16, 2026 · price × 22.69M shares outstanding
Karyopharm Therapeutics Inc. logo
Ticker
NASDAQ:KPTI
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Karyopharm Therapeutics (NASDAQ:KPTI) Q2 2026 Earnings Call

    Thu, Aug 13, 2026 · 8:00 AM ET

    Watch Transcript

  • Karyopharm Therapeutics (NASDAQ:KPTI) Q1 2026 Earnings Call

    Thu, May 14, 2026 · 8:00 AM ET

    Watch Transcript

  • Karyopharm Therapeutics (NASDAQ:KPTI) Q4 2025 Earnings Call

    Thu, Feb 12, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2026

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

Aug 31, 2026

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

Aug 13, 2026

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

Aug 10, 2026

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Jul 30, 2026

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

Jul 30, 2026

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Jun 3, 2026

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

Jun 2, 2026

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

Jun 1, 2026

Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

All Karyopharm Therapeutics Inc. news

Decks

Karyopharm Therapeutics Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
24 in the last 12 months · 177 in all · newest Oct 1, 2026 · oldest 2019
Calls
22 calls with a replay · 22 with a transcript · latest Aug 13, 2026
Decks
27 decks · latest Aug 13, 2026

Where Karyopharm Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KPTI · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A40YLCLS ExchangeGermanyEUR
Lang & Schwarz:A40YLCLang & SchwarzGermanyEUR
gettex:25K0gettexGermanyEUR
BX Swiss:KPTIBX SwissSwitzerlandCHF
Tradegate:25K0TradegateGermanyEUR
BOATS:KPTIBOATSUnited StatesUSD
Dusseldorf:25K0DusseldorfGermanyEUR
Frankfurt:25K0FrankfurtGermanyEUR
Munich:25K0MunichGermanyEUR
Stuttgart:25K0StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Karyopharm Therapeutics Inc.